CollaGenex Pharmaceuticals Provides Update on 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
Wednesday May 2, 7:00 am ET
NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI - News) today announced that it has learned that one patient has experienced apparent significant photo-toxicity, a known side effect of tetracyclines, while participating in the 40 mg cohort of its Phase II dose-finding study of incyclinide for the treatment of acne. The Company is currently investigating this adverse event and has suspended enrollment of all new patients in the study. After completing its investigation, CollaGenex will meet with the FDA to discuss the ongoing development program for incyclinide.
Colin Stewart, president and chief executive officer of CollaGenex, said, "Our principal concern is the safety of our patients, and we are suspending further enrollment in the 40 mg cohort of this trial while we investigate this adverse event. Since we observed no adverse events at lower doses, we are continuing the Phase II dose-finding trial of incyclinide for the treatment of rosacea."
Conference Call
As previously announced, CollaGenex will hold a conference call on Wednesday, May 2, at 11:00 a.m. Eastern Daylight Time to discuss the Company's first quarter 2007 financial results and the contents of this press release. Investors and other interested parties may access the conference call by dialing (888) 694-4728 in the U.S. or (973) 582-2745 internationally, or via a live webcast on the Company's website at www.collagenex.com.
For those who cannot listen to the live webcast, a replay will be available shortly after the call at www.collagenex.com for 90 days. Additionally, a recording of the call will be available by telephone until 11:59 p.m. on May 9, 2006 by dialing (877) 519-4471 in the U.S. or (973) 341-3080 internationally, and entering access code 8696027. |
